Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Oric Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Oric Pharmaceuticals, Inc.

ORIC

Oric Pharmaceuticals, Inc.

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals is a biopharmaceutical company focused on developing therapies that overcome resistance in cancer. Its pipeline includes targeted treatments for hormone-dependent cancers, precision oncology, and tumor dependencies, with a focus on resistant solid tumors like lung and prostate cancers. The company leverages biomarker-driven approaches, internal discovery capabilities, and strategic collaborations to deliver innovative, targeted cancer therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Oric Pharmaceuticals, Inc.

1
1
Oric Pharmaceuticals, Inc. ORIC Pharmaceuticals Reports $35.8 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Oric Pharmaceuticals, Inc. Oric Pharmaceuticals Reports $129.5 Million Net Loss, Focuses on Lead Programs

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Oric Pharmaceuticals, Inc. ORIC Pharmaceuticals Reports Q3 2025 Financial Results with $32.6 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Oric Pharmaceuticals, Inc. ORIC Pharmaceuticals Reports $36.4 Million Net Loss in Q2 2025, Increases Focus on Key Clinical Programs

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Oric Pharmaceuticals, Inc. ORIC Pharmaceuticals Reports $30M Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Oric Pharmaceuticals, Inc. Oric Pharmaceuticals Reports $127.8 Million Net Loss for 2024, Driven by Increased R&D Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Oric Pharmaceuticals, Inc. ORIC Pharmaceuticals Reports Increased Assets, Operating Losses, and Financing Activities in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments